This study is currently not recruiting participants.

A Phase 1/2 First in Human Single-arm Open-label Study of Once a Day Orally Administered BMN673 in Patients with Advanced or Recurrent Solid Tumors

Investigation of an Investigational Medication for Advanced Tumors

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to test the safety of a new experimental drug called BMN 673 and see what effects it has on cancer.

Detailed description of study

This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with advanced tumors with DNA-repair pathway deficiencies. There will be 2 parts to the study: a dose escalati

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Solid Tumor
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safety of an investigational medication in patients with advanced tumors that have problems in their DNA repair pathways. The purpose is to observe the effects of this medication on cancer.

Participants will receive the investigational medication and the study will include assessments of how the body processes the medication and its effects on the body.

  • Who can participate: The study is open to adults aged 18 and older with advanced tumors. Key eligibility factors include specific genetic markers related to DNA repair issues.
  • Study details: Participants will take part in a study with two parts: a dose escalation phase and a further assessment phase. A placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine, is not used in this study.
Updated on 19 Feb 2024. Study ID: 1107006397

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team